PHARMACEUTICAL NEWS

• Oral Anticoagulant Approved By European Commission
  Bayer’s once-daily oral anticoagulant rivaroxaban (Xarelto®), has received final approval from the European Commission for the prevention of DVT and PE in patients undergoing hip or knee replacement surgery. Rivaroxaban, which does not require monitoring of coagulation tests, demonstrated superior efficacy compared to enoxaparin in a pivotal phase III trial.
  
  

We welcome your comments and suggestions regarding content and format at primelines@primeoncology.org.